Ferroptosis in drug resistant glioma

耐药神经胶质瘤中的铁死亡

基本信息

  • 批准号:
    10808297
  • 负责人:
  • 金额:
    $ 12.87万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-19 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

Project Abstract Cancer drug resistance is the last frontier in extending patient overall survival, especially in the deadly brain tumor – glioblastoma (GBM). GBM currently has one standard of care chemotherapeutic agent – temozolomide (TMZ) – which extends median overall survival to ~14-16 months. However, TMZ resistance is rapid and uniformly fatal. Yet, because there are some long-term responders (~5% at 5 years), almost all newly diagnosed GBMs will receive TMZ, making TMZ-resistance a major clinical unmet need, and the focus of my previous, current, and future work. The central goal of my current work is to better understand the distinct changes in the metabolic states between TMZ-Sensitive (TMZ-S) and -Resistant (TMZ-R) disease, allowing for the discovery of therapeutically targetable vulnerabilities. To this end, I have found that TMZ-R cells have a greater dependence on cystine import, increase of intracellular iron, and a maintained oxidative state that primes these TMZ-R models for cyst(e)ine depletion-induced ferroptosis with a known neuroprotective agent – ebselen. I further show that this form of ferroptosis – or iron-dependent cell death – could be induced by the selenium in ebselen or TMZ-Selenium but not a TMZ-Sulfur analog in TMZ-R cells, which will no longer have a response to TMZ alone. Therefore, the objective of this project is to meticulously characterize this cyst(e)ine depletion- induced ferroptosis phenotype in TMZ-R models where it will both help in our understanding of TMZ-R GBM and develop a framework where small molecule selenium-containing compounds could be of use in other diseases. To accomplish this goal, I will take full advantage of my excellent mentoring/advisory committee as well as the exceptional resources and training environment available to me at Northwestern University. The expected outcomes of this project include a thorough understanding of the metabolic landscape and changes between both TMZ-S and -R models, as well as shifts post cyst(e)ine depletion-induced ferroptosis (Aim 1). A characterization and validation of the protein players that are necessary to mediate cyst(e)ine depletion-induced ferroptosis in TMZ-R models, as well as how the increased oxidative state in TMZ-R may affect enzymatic active site status that would not be discovered via sequencing methods but is essential for protein activity (Aim 2). Finally, the mechanistic knowledge gained from a meticulous understanding of both the metabolic readouts and proteomic players will allow for a smarter animal model design to answer and/or confirm the findings in Aim 1 & 2 (Aim 3). As I already have a strong background in RNA biology/splicing and DNA damage/structure in TMZ-R disease, this proposal will strengthen my knowledge in the metabolic differences and learn proteomic and metabolic techniques. In this way, I will have a well-rounded understanding of TMZ-R disease which will help me to design smarter and more complete studies in the future when I run my own independent lab.
项目摘要 癌症耐药性是延长患者总体生存期的最后前沿,尤其是在致命的情况下 脑肿瘤——胶质母细胞瘤(GBM)目前有一种标准治疗化疗药物—— 替莫唑胺 (TMZ)——可将中位总生存期延长至约 14-16 个月,但 TMZ 耐药性是存在的。 然而,因为有一些长期反应者(5 年时约 5%),而且几乎都是新的。 诊断出的 GBM 将接受 TMZ,这使得 TMZ 耐药成为主要的临床未满足需求,也是我的重点 我当前工作的中心目标是更好地理解不同的工作。 TMZ 敏感 (TMZ-S) 和耐药 (TMZ-R) 疾病之间代谢状态的变化,从而允许 为此,我发现 TMZ-R 细胞具有一个可靶向治疗的弱点。 对胱氨酸输入的更大依赖性、细胞内铁的增加以及维持的氧化状态 这些 TMZ-R 模型用于使用已知的神经保护剂 – 依布硒啉 (ebselen) 来检测半胱氨酸消耗引起的铁死亡。 我进一步表明,这种形式的铁死亡(或铁依赖性细胞死亡)可以由硒诱导 依布硒啉或 TMZ-硒,但不是 TMZ-R 细胞中的 TMZ-硫类似物,后者将不再对 因此,该项目的目标是仔细表征这种半胱氨酸消耗 - 在 TMZ-R 模型中诱导铁死亡表型,这将有助于我们了解 TMZ-R GBM 和 开发一个框架,使小分子含硒化合物可用于其他疾病。 为了实现这一目标,我将充分利用我优秀的指导/顾问委员会以及 西北大学为我提供了卓越的资源和培训环境。 该项目的成果包括对代谢格局和之间的变化的透彻了解 TMZ-S 和 -R 模型,以及半胱氨酸耗尽后诱导的铁死亡(目标 A)。 介导半胱氨酸耗竭所必需的蛋白质参与者的表征和验证 TMZ-R 模型中的铁死亡,以及 TMZ-R 中氧化状态的增加如何影响酶活性 位点状态无法通过测序方法发现,但对于蛋白质活性至关重要(目标 2)。 最后,通过对代谢读数和代谢读数的细致理解而获得的机械知识 蛋白质组参与者将允许更智能的动物模型设计来回答和/或确认目标 1 和中的发现 2(目标 3),因为我已经在 TMZ-R 的 RNA 生物学/剪接和 DNA 损伤/结构方面拥有深厚的背景。 疾病,这个建议将加强我对代谢差异的了解,并学习蛋白质组学和 通过这种方式,我将对 TMZ-R 疾病有一个全面的了解,这将有助于我。 当我将来经营自己的独立实验室时,可以设计更智能、更完整的研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Deanna Marie Tiek其他文献

Deanna Marie Tiek的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Deanna Marie Tiek', 18)}}的其他基金

Novel relationships of splicing factors in temozolomide-resistant glioblastoma
替莫唑胺耐药胶质母细胞瘤中剪接因子的新关系
  • 批准号:
    10085005
  • 财政年份:
    2020
  • 资助金额:
    $ 12.87万
  • 项目类别:
Novel relationships of splicing factors in temozolomide-resistant glioblastoma
替莫唑胺耐药胶质母细胞瘤中剪接因子的新关系
  • 批准号:
    10557860
  • 财政年份:
    2020
  • 资助金额:
    $ 12.87万
  • 项目类别:
Novel relationships of splicing factors in temozolomide-resistant glioblastoma
替莫唑胺耐药胶质母细胞瘤中剪接因子的新关系
  • 批准号:
    10334507
  • 财政年份:
    2020
  • 资助金额:
    $ 12.87万
  • 项目类别:

相似海外基金

Structure-based Antiviral Design against HTLV-1 Protease
基于结构的 HTLV-1 蛋白酶抗病毒设计
  • 批准号:
    10750889
  • 财政年份:
    2023
  • 资助金额:
    $ 12.87万
  • 项目类别:
Unraveling the PTEN Interactome: Modeling Structural and Functional Dynamic Network Architecture for Therapeutic Modulation in Cancer and Autism
揭开 PTEN 相互作用组:为癌症和自闭症治疗调节的结构和功能动态网络架构建模
  • 批准号:
    10439873
  • 财政年份:
    2021
  • 资助金额:
    $ 12.87万
  • 项目类别:
Unraveling the PTEN Interactome: Modeling Structural and Functional Dynamic Network Architecture for Therapeutic Modulation in Cancer and Autism
揭开 PTEN 相互作用组:为癌症和自闭症治疗调节的结构和功能动态网络架构建模
  • 批准号:
    10282792
  • 财政年份:
    2021
  • 资助金额:
    $ 12.87万
  • 项目类别:
Crystallographic and NMR studies of the Human Cytochrome P450 enzyme responsible for inactivating vitamin D
负责使维生素 D 失活的人类细胞色素 P450 酶的晶体学和核磁共振研究
  • 批准号:
    9343024
  • 财政年份:
    2015
  • 资助金额:
    $ 12.87万
  • 项目类别:
Crystallographic and NMR studies of the Human Cytochrome P450 enzyme responsible for inactivating vitamin D
负责使维生素 D 失活的人类细胞色素 P450 酶的晶体学和核磁共振研究
  • 批准号:
    9021675
  • 财政年份:
    2015
  • 资助金额:
    $ 12.87万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了